奥美医疗用品股份有限公司 关于参加湖北辖区上市公司 2025 年投资者 证券代码：002950 证券简称：奥美医疗 公告编号：2025-035 奥美医疗用品股份有限公司 董事会 2025 年 6 月 7 日 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参 与本次互动交流，活动时间为 2025 年 6 月 12 日（周四）14:00-16:40，其中投 资者网上互动交流时间为 15:40-16:40。届时公司高管将在线就公司 2024 年度 业绩、公司治理、发展战略、经营状况、股份回购等投资者关心的问题，与投 资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，奥美医疗用品股份有限公司（以下简 称"公司"）将参加由湖北证监局、湖北省上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年湖北辖区上市公司投资者集体接待日活动"，现将相 关事项公告如下： 网上集体接 ...

证券代码：002950 证券简称：奥美医疗 公告编号：2025-034 奥美医疗用品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 一、会议召开和出席情况 （1）现场会议时间：2025 年 6 月 4 日（星期三）14：30 （2）网络投票时间：2025 年 6 月 4 日（星期三） ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 ②通过深圳证券交易所五联网投票系统投票的具体时间为：2025 年 6 月 4 日上午 9：15 至下午 15：00 期间的任意时间。 会规则》《深圳证券交易所股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《奥美医疗用品股份有限公司章程》的有关规定。 二、会议出席情况 （一）股东出席的总体情况 参加本次股东大会现场会议和网络投票表决的股东及股东代理人共 232 人， 代表有表决权的公司股份数合计为 420,680,344 股，占公司有表决权股份总数 权的公司股份数合计为 334,993,030 股，占公司有表决权股份总数 618,757,897 股的 54.1396%；通过网络 ...

Core Viewpoint - The legal opinion provided by Beijing Deheng (Nanjing) Law Firm confirms the legality and validity of the procedures, participants, and voting results of the 2024 Annual General Meeting of Aomei Medical Supplies Co., Ltd. [1][10] Group 1: Meeting Procedures - The third meeting of the board of directors approved the proposal to convene the annual general meeting on April 24, 2025 [2] - The meeting was postponed to June 4, 2025, while the record date for shareholding remained unchanged on May 26, 2025 [3][4] - The meeting was conducted with a combination of on-site voting and online voting, adhering to the previously disclosed arrangements [4] Group 2: Participant Qualifications - A total of 232 shareholders or their proxies attended the meeting, representing 13,622,310 shares, which is 2.2016% of the total voting shares [5] - Among them, 225 shareholders participated through online voting, representing 85,687,314 shares, which is 13.8483% of the total voting shares [5] Group 3: Voting Procedures and Results - The meeting utilized both on-site and online voting methods, with all proposed resolutions being voted on without any postponement [6] - The voting results showed that the resolutions were overwhelmingly approved, with the highest approval rate being 99.8124% for one of the proposals [6][7][8][9] - The legal opinion concludes that the voting procedures and results comply with relevant laws and regulations [10]

北京德恒（南京）律师事务所 2024年年度股东大会的法律意见 关于奥美医疗用品股份有限公司 北京德恒（南京）律师事务所 关于 奥美医疗用品股份有限公司 2024 年年度股东大会的法律意见 德恒18G20240237号 致： 奥美医疗用品股份有限公司 北京德恒（南京）律师事务所接受奥美医疗用品股份有限公司（以下简称"公 司 "）委托，指派蔡丹律师、赵米悦律师（以下简称"本所律师"）出席公司 2024 年年度股东大会（以下简称"本次股东大会"），对本次股东大会的合法性 进行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等现行有效的法律、法规、规范性文件以及《奥 美医疗用品股份有限公司章程（以下简称"《公司章程》"）的规定而出具。 为出具本法律意见，本所律师审查了公司本次股东大会的有关文件和材料， 同时本所律师出席本次股东大会会议，依法参与了现场参会人员身份证明文件的 核验工作，见证了本次股东大会召开、表决和形成决议的全过程。 本法律意见仅供见证公司本次股东大会相关事 ...

2024 年年度股东大会决议公告 证券代码：002950 证券简称：奥美医疗 公告编号：2025-034 奥美医疗用品股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 一、会议召开和出席情况 6、 本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东 会规则》《深圳证券交易所股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《奥美医疗用品股份有限公司章程》的有关规定。 二、会议出席情况 （一）股东出席的总体情况 参加本次股东大会现场会议和网络投票表决的股东及股东代理人共 232 人， 1、 本次股东大会不存在否决议案的情形。 2、 本次股东大会不涉及变更以往股东大会已通过的决议。 1、 召开时间： （1）现场会议时间：2025 年 6 月 4 日（星期三）14：30 （2）网络投票时间：2025 年 6 月 4 日（星期三） ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 6 月 4 日上午 9：15--9：25、9：30-11：30，下午 13：00-15：00； ②通过深圳证券交易所五联网投票系 ...

一、股份回购实施进展 截至 2025 年 5 月 31 日，公司累计通过深圳证券交易所交易系统以集中竞价交易方式 回购公司股份 1,987,400股，占公司目前总股本的比例为 0.3138%，最高成交价为 9.26元 /股，最低成交价为 8.33 元/股，支付的总金额为 18,001,207.00 元（不含印花税、交易佣 金等交易费用）。 二、其他说明 截至目前，本次回购实施情况与回购股份方案不存在差异。公司后续将根据市场情况 在回购期限内实施本次回购计划，并按照相关法律法规的规定及时履行信息披露义务。敬 请广大投资者关注后续公告，并注意投资风险。 证券代码：002950 证券简称：奥美医疗 公告编号：2025-033 奥美医疗用品股份有限公司 关于股份回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开第 三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司以自有资金及股票回购专项贷款资金通过集中竞价交易方式回购公司股 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aomei Medical, indicating a low PE ratio compared to the industry average, suggesting potential undervaluation [1][3] - As of June 3, Aomei Medical's stock closed at 8.84 yuan, with a rolling PE ratio of 15.49, which is the lowest in 39 days, and a total market capitalization of 5.598 billion yuan [1] - The medical device industry has an average PE ratio of 50.80, with Aomei Medical ranking 37th among its peers [1] Group 2 - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2] - The company has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei and recognized for its intelligent manufacturing projects [2] - In the first quarter of 2025, Aomei Medical reported a revenue of 759 million yuan, a year-on-year increase of 1.64%, while net profit decreased by 7.86% to 86.5 million yuan, with a gross profit margin of 30.52% [3]

Core Viewpoint - Aomei Medical (002950) is focusing on maintaining shareholder returns while investing in strategic upgrades and new product development in the medical device sector, particularly in advanced dressing products and overseas markets [1][2][3]. Company Performance - As of May 30, 2025, Aomei Medical's stock closed at 8.69 yuan, with a market capitalization of 5.503 billion yuan, ranking 56th in the medical device sector [1]. - The company reported a total revenue of 758.66 million yuan for Q1 2025, a year-on-year increase of 1.64%, while net profit decreased by 7.94% to 86.65 million yuan, with a net profit margin of 11.42% [5][7]. Dividend Policy - The company has distributed a total cash dividend of approximately 91.91 million yuan over the last three years, exceeding 30% of the average annual net profit, and plans to continue prioritizing shareholder returns despite reduced dividends in recent years due to strategic investments [1][2]. Product Development and Market Strategy - Aomei Medical is focusing on high-value medical devices, particularly in advanced dressing products, with plans to launch new functional dressing products in 2024 [2][3]. - The company aims to enhance its competitive edge through automation and smart technology in manufacturing, while also expanding its product offerings in the hygiene care sector [6][8]. International Market Presence - In 2024, Aomei Medical achieved overseas revenue of 275.65 million yuan, a 23.43% increase year-on-year, with a significant market share in developed regions such as the US and Europe [3][4]. - The company is actively expanding into emerging markets in the Middle East, South America, and Southeast Asia to reduce reliance on developed markets [4]. Industry Outlook - The medical dressing market is characterized as a stable growth sector with strong demand, and Aomei Medical is well-positioned to maintain its competitive advantage and market share [8].

Group 1 - The core viewpoint of the news highlights the financial performance and market position of Aomei Medical, indicating a decline in stock price and a lower PE ratio compared to the industry average [1][3] - As of May 26, Aomei Medical's stock closed at 8.6 yuan, down 1.04%, with a rolling PE ratio of 15.07 times and a total market capitalization of 5.446 billion yuan [1] - The medical device industry has an average PE ratio of 48.92 times, with Aomei Medical ranking 37th among its peers [1] Group 2 - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2] - The company has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei and recognized for its intelligent manufacturing projects [2] - In the first quarter of 2025, Aomei Medical reported a revenue of 759 million yuan, a year-on-year increase of 1.64%, while net profit decreased by 7.86% to 86.5 million yuan, with a gross profit margin of 30.52% [3]

Group 1: Financial Performance - The total cash dividend amount for the last three accounting years reached 91,913,104.51 CNY, exceeding 30% of the average net profit for the same period [2] - Cumulative cash dividends from 2018 to 2024 amount to approximately 1.099 billion CNY, which is 2.29 times the net raised funds [2] - In Q1 2025, total revenue was 758,656,819.43 CNY, a year-on-year increase of 1.64%, while net profit was 86,652,875.66 CNY, a decrease of 7.94% [5][7] Group 2: Market Position and Strategy - The company has achieved a high market share in overseas markets, with 2024 foreign revenue at 275,650.05 CNY, up 23.43%, accounting for 82.87% of total revenue [5] - The company has maintained its position as the leading exporter of medical dressings in China for 17 consecutive years since 2008 [6] - Future growth will focus on four product categories: surgical and wound care, infection prevention, advanced dressings, and hygiene care products [6] Group 3: Product Development and Innovation - The company is transitioning from basic to advanced dressing products, with new offerings in 2024 including soft silicone foam dressings and hydrocolloid dressings [3][6] - The company is investing in technology integration, including AI for quality control, to enhance manufacturing competitiveness [4] - The hygiene care product line is still in its early stages but has significant growth potential, targeting a market valued in the hundreds of billions [6][8] Group 4: Industry Outlook - The medical dressing market is characterized as a stable growth sector with low product substitutability, provided that companies maintain competitive advantages [7] - The company aims to reduce reliance on developed markets by expanding into emerging markets in the Middle East, South America, Southeast Asia, and Africa [5]